Skip to content

Lifecore Biomedical, Inc. LFCR Payment, Tax Withholding, Share-Based Payment Arrangement

Payment, Tax Withholding, Share-Based Payment Arrangement at other companies

BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$1.19M-12.1%
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO

Other financials

Income statement

See full
Revenue$23.2M-36.4%
Gross profit$4.5M-68.1%
Operating income-$4.7M
Net income-$15.0M-1,206%
EPS (diluted)-$0.43-1,333%

Balance sheet

See full
Cash & equivalents$20.8M+152%
Total debt$156.9M+1,310%
Total equity-$28.4M-2,229%
Total assets$225.5M-5.8%

Cash flow

See full
Operating cash flow$4.7M
CapEx$1.1M-46.7%
Free cash flow$3.6M

Valuation

See full
Market cap$196.92M-35.4%
Enterprise value$333.06M+8.3%
P/S1.6×+0.5×

Profitability

See full
Gross margin31.3%-1.4pp
Operating margin-14.5%-2.2pp
Net margin-30%
FCF margin-36.4%

Returns & leverage

See full
Return on equity-612.1%
Debt / equity8.3×-1.5×
Current ratio3.8×+0.9×

Where this comes from

Reported directly by Lifecore Biomedical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation.

The official record: Lifecore Biomedical, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lifecore Biomedical, Inc.'s payment, tax withholding, share-based payment arrangement.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lifecore Biomedical, Inc.'s payment, tax withholding, share-based payment arrangement?
Lifecore Biomedical, Inc. (LFCR) reported payment, tax withholding, share-based payment arrangement of $0 in Q1 2026.
How has Lifecore Biomedical, Inc.'s payment, tax withholding, share-based payment arrangement changed year-over-year?
Lifecore Biomedical, Inc.'s payment, tax withholding, share-based payment arrangement decreased by 100.0% year-over-year, from $163K to $0.
What is the long-term trend for Lifecore Biomedical, Inc.'s payment, tax withholding, share-based payment arrangement?
Over 3 years (2022 to 2025), Lifecore Biomedical, Inc.'s payment, tax withholding, share-based payment arrangement has grown at a 17.2% compound annual growth rate (CAGR), from $789K to $1.27M.